logo BDSP

Base documentaire

  1. An economic analysis of different strategies of immunization against hepatitis A virus in developed countries.

    Article - En anglais

    Acute hepatitis A is a major public health problem in developed countries, and because a large proportion of patients with acute hepatitis A do not have any identifiable risk factors, current practice of targeting the high-risk groups for vaccination against hepatitis A virus (HAV) is unlikely to have a significant impact on the overall incidence of acute hepatitis A. No economic analysis of strategies of mass immunization against HAV is available.

    Three different strategies of immunization against HAV using commercially available inactivated vaccine were compared in a Markov model analysis of a cohort of 2-year-old healthy children in a developed country.

    In strategy I, universal vaccination was pursued.

    In strategy II, children were initially screened for antibody and, if susceptible, they were vaccinated.

    In strategy III, no vaccination was offered.

    Cost per person and quality adjusted life-years (QALY) gained in each strategy were the outcome measures compared.

    The baseline analysis showed that strategy II is more cost-effective than strategy I, with marginal cost-effectiveness ratios of $7,267.67 and $12,833.34, respectively, compared with a strategy of no intervention.

    Sensitivity analysis showed that if the cost of the two-dose vaccine could be reduced to less than $57, the strategy of universal vaccination would be the preferred immunization strategy. (...)

    Mots-clés Pascal : Hépatite virale A, Virose, Infection, Virus hépatite A, Hepatovirus, Picornaviridae, Virus, Prévention, Immunisation, Vaccination, Indication, Risque élevé, Analyse avantage coût, Animal, Appareil digestif pathologie, Foie pathologie, Economie santé

    Mots-clés Pascal anglais : Viral hepatitis A, Viral disease, Infection, Hepatitis A virus, Hepatovirus, Picornaviridae, Virus, Prevention, Immunization, Vaccination, Indication, High risk, Cost benefit analysis, Animal, Digestive diseases, Hepatic disease, Health economy

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0119722

    Code Inist : 002B30A01C. Création : 16/11/1999.